当前位置： SCI文献检索 > CANCER CELL期刊下所有文献 > No need for constant help: human IgG2 antibodies have an autonomous agonistic activity for immunotherapy of cancer.

No need for constant help: human IgG2 antibodies have an autonomous agonistic activity for immunotherapy of cancer.

Abstract：

:Agonistic antibodies specific for members of the tumor necrosis factor receptor protein family hold great promise for immunotherapy of cancer. In this issue of Cancer Cell, White and colleagues provide evidence that the human IgG2 subclass may represent a superior backbone for the use of these antibodies in human therapy.

journal_name

Cancer Cell

journal_title

Cancer cell

authors

Lux A,Nimmerjahn F

doi

10.1016/j.ccell.2014.12.010

subject

Has Abstract

pub_date

2015-01-12 00:00:00

pages

10-1

issue

1

eissn

1535-6108

issn

1878-3686

pii

S1535-6108(14)00519-4

journal_volume

27

pub_type

评论,杂志文章

相关文献

CANCER CELL文献大全
  • PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress.

    abstract：:Cancer cells reprogram their metabolism using different strategies to meet energy and anabolic demands to maintain growth and survival. Understanding the molecular and genetic determinants of these metabolic programs is critical to successfully exploit them for therapy. Here, we report that the oncogenic melanocyte li...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2012.11.020

    authors： Vazquez F,Lim JH,Chim H,Bhalla K,Girnun G,Pierce K,Clish CB,Granter SR,Widlund HR,Spiegelman BM,Puigserver P

    更新日期：2013-03-18 00:00:00

  • Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease.

    abstract：:Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disease (MPD) initiated by expression of the p210-BCR-ABL fusion protein. We demonstrate in a murine model of p210-BCR-ABL-induced MPD that gene targeting of Rac1 and Rac2 significantly delays or abrogates disease development. Attenuation of the disease...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2007.10.015

    authors： Thomas EK,Cancelas JA,Chae HD,Cox AD,Keller PJ,Perrotti D,Neviani P,Druker BJ,Setchell KD,Zheng Y,Harris CE,Williams DA

    更新日期：2007-11-01 00:00:00

  • Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis.

    abstract：:Benign neurofibromas and malignant peripheral nerve sheath tumors are serious complications of neurofibromatosis type 1. The epidermal growth factor receptor is not expressed by normal Schwann cells, yet is overexpressed in subpopulations of Nf1 mutant Schwann cells. We evaluated the role of EGFR in Schwann cell tumor...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2004.10.016

    authors： Ling BC,Wu J,Miller SJ,Monk KR,Shamekh R,Rizvi TA,Decourten-Myers G,Vogel KS,DeClue JE,Ratner N

    更新日期：2005-01-01 00:00:00

  • A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer.

    abstract：:Elucidating the determinants of aggressiveness in lethal prostate cancer may stimulate therapeutic strategies that improve clinical outcomes. We used experimental models and clinical databases to identify GATA2 as a regulator of chemotherapy resistance and tumorigenicity in this context. Mechanistically, direct upregu...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2014.11.013

    authors： Vidal SJ,Rodriguez-Bravo V,Quinn SA,Rodriguez-Barrueco R,Lujambio A,Williams E,Sun X,de la Iglesia-Vicente J,Lee A,Readhead B,Chen X,Galsky M,Esteve B,Petrylak DP,Dudley JT,Rabadan R,Silva JM,Hoshida Y,Lowe SW,Cordo

    更新日期：2015-02-09 00:00:00

  • Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia.

    abstract：:Activating mutations in the FLT3 receptor tyrosine kinase occur in 30% of patients with acute myeloid leukemia. Small molecule FLT3 kinase inhibitors show selective antitumor activity in preclinical models. Clinical studies are underway. ...

    journal_title：Cancer cell

    pub_type： 杂志文章,评审

    doi：10.1016/s1535-6108(02)00080-6

    authors： Sawyers CL

    更新日期：2002-06-01 00:00:00

  • Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.

    abstract：:Recent structural studies of epidermal growth factor receptor (EGFR) family extracellular regions have identified an unexpected mechanism for ligand-induced receptor dimerization that has important implications for activation and inhibition of these receptors. Here we describe the 2.8 angstroms resolution X-ray crysta...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2005.03.003

    authors： Li S,Schmitz KR,Jeffrey PD,Wiltzius JJ,Kussie P,Ferguson KM

    更新日期：2005-04-01 00:00:00

  • Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.

    abstract：:We characterized the landscape and drug sensitivity of ERBB2 (HER2) mutations in cancers. In 11 datasets (n = 211,726), ERBB2 mutational hotspots varied across 25 tumor types. Common HER2 mutants yielded differential sensitivities to eleven EGFR/HER2 tyrosine kinase inhibitors (TKIs) in vitro, and molecular dynamics s...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2019.09.001

    authors： Robichaux JP,Elamin YY,Vijayan RSK,Nilsson MB,Hu L,He J,Zhang F,Pisegna M,Poteete A,Sun H,Li S,Chen T,Han H,Negrao MV,Ahnert JR,Diao L,Wang J,Le X,Meric-Bernstam F,Routbort M,Roeck B,Yang Z,Raymond VM,Lanman

    更新日期：2019-10-14 00:00:00

  • CD103+ dendritic cells producing interleukin-12 in anticancer immunosurveillance.

    abstract：:The mechanisms through which tumor antigen-specific T cells are elicited in natural or chemotherapy-induced immunosurveillance have been elusive. In this issue of Cancer Cell, two papers by Broz and colleagues and Ruffell and colleagues delineate an important role for a specific dendritic cell subset characterized by ...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccell.2014.10.008

    authors： Zitvogel L,Kroemer G

    更新日期：2014-11-10 00:00:00

  • ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma.

    abstract：:Amplification of 1q21 occurs in approximately 30% of de novo and 70% of relapsed multiple myeloma (MM) and is correlated with disease progression and drug resistance. Here, we provide evidence that the 1q21 amplification-driven overexpression of ILF2 in MM promotes tolerance of genomic instability and drives resistanc...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2017.05.011

    authors： Marchesini M,Ogoti Y,Fiorini E,Aktas Samur A,Nezi L,D'Anca M,Storti P,Samur MK,Ganan-Gomez I,Fulciniti MT,Mistry N,Jiang S,Bao N,Marchica V,Neri A,Bueso-Ramos C,Wu CJ,Zhang L,Liang H,Peng X,Giuliani N,Draetta G

    更新日期：2017-07-10 00:00:00

  • A tell-tail sign of chromatin: histone mutations drive pediatric glioblastoma.

    abstract：:Recent genomic analyses of pediatric glioblastoma, a poorly understood tumor with dismal outcome, have identified mutations in histone H3 variants that affect critical amino acids in the tail. The findings extend discoveries of chromatin regulator inactivation and gain-of-function mutations by documenting alteration o...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2012.03.001

    authors： Rheinbay E,Louis DN,Bernstein BE,Suvà ML

    更新日期：2012-03-20 00:00:00

  • The ups and downs of SRC regulation: tumor suppression by Cbp.

    abstract：:Tight control of the tyrosine kinase activity of c-Src is critical for regulating its oncogenic potential. In a recent issue of Molecular Cell, Oneyama et al. (2008a) report that the membrane-bound adaptor protein Cbp (also known as PAG) can suppress c-Src-mediated cell transformation and tumorigenesis by binding and ...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2008.05.011

    authors： Resh MD

    更新日期：2008-06-01 00:00:00

  • CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis.

    abstract：:A large body of evidence indicates that chronic inflammation is one of several key risk factors for cancer initiation, progression, and metastasis. However, the underlying mechanisms responsible for the contribution of inflammation and inflammatory mediators to cancer remain elusive. Here, we present genetic evidence ...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2013.10.009

    authors： Katoh H,Wang D,Daikoku T,Sun H,Dey SK,Dubois RN

    更新日期：2013-11-11 00:00:00

  • A molecular view of anti-ErbB monoclonal antibody therapy.

    abstract：:Abnormal activation of the epidermal growth factor receptor (EGFR) and its homolog HER2 (Neu/ErbB2) has been associated with many human cancers, and monoclonal antibodies targeting EGFR and HER2 are effective anticancer therapies. Structural studies of these receptors and antibodies have revealed much about how they f...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccr.2008.03.010

    authors： Leahy DJ

    更新日期：2008-04-01 00:00:00

  • Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes.

    abstract：:We identified dynein light chain 1 (DLC1) as a physiologic substrate of p21-activated kinase 1 (Pak1). Pak1-DLC1 interaction plays an essential role in cell survival, which depends on Pak1's phosphorylation of DLC1 on Ser88. Pak1 associates with the complex of DLC1 and BimL, a proapoptotic BH3-only protein, and phosph...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2004.05.022

    authors： Vadlamudi RK,Bagheri-Yarmand R,Yang Z,Balasenthil S,Nguyen D,Sahin AA,den Hollander P,Kumar R

    更新日期：2004-06-01 00:00:00

  • Advancing the field of drug delivery: taking aim at cancer.

    abstract：:Drug delivery systems for cancer therapeutics have now been used by millions of patients and have resulted in the creation of new therapies as well as significantly improving existing ones. Here we discuss a number of the drug delivery systems that have been approved by regulatory authorities and that are currently in...

    journal_title：Cancer cell

    pub_type： 杂志文章,评审

    doi：10.1016/s1535-6108(03)00276-9

    authors： Moses MA,Brem H,Langer R

    更新日期：2003-11-01 00:00:00

  • Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation.

    abstract：:Chronic exposure to tobacco smoke, which contains over 60 tumor-initiating carcinogens, is the major risk factor for development of lung cancer, accounting for a large portion of cancer-related deaths worldwide. It is well established that tobacco smoke is a tumor initiator, but we asked whether it also acts as a tumo...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2009.12.008

    authors： Takahashi H,Ogata H,Nishigaki R,Broide DH,Karin M

    更新日期：2010-01-19 00:00:00

  • Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia.

    abstract：:Studying mechanisms of malignant transformation of human pre-B cells, we found that acute activation of oncogenes induced immediate cell death in the vast majority of cells. Few surviving pre-B cell clones had acquired permissiveness to oncogenic signaling by strong activation of negative feedback regulation of Erk si...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2015.05.008

    authors： Shojaee S,Caeser R,Buchner M,Park E,Swaminathan S,Hurtz C,Geng H,Chan LN,Klemm L,Hofmann WK,Qiu YH,Zhang N,Coombes KR,Paietta E,Molkentin J,Koeffler HP,Willman CL,Hunger SP,Melnick A,Kornblau SM,Müschen M

    更新日期：2015-07-13 00:00:00

  • NEDD8 pathways in cancer, Sine Quibus Non.

    abstract：:There are 17 known ubiquitin-like proteins (UBLs) from nine phylogenetically distinct classes (NEDD8, SUMO, ISG15, FUB1, FAT10, Atg8, Atg12, Urm1, and UFM1) that have been identified to conjugate to substrates in a manner analogous to ubiquitin. NEDD8 is one of the most studied UBLs and shares the highest amino acid s...

    journal_title：Cancer cell

    pub_type： 杂志文章,评审

    doi：10.1016/j.ccr.2011.01.002

    authors： Watson IR,Irwin MS,Ohh M

    更新日期：2011-02-15 00:00:00

  • The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53.

    abstract：:Gankyrin is an ankyrin repeat oncoprotein commonly overexpressed in hepatocellular carcinomas. Gankyrin interacts with the S6 proteasomal ATPase and accelerates the degradation of the tumor suppressor Rb. We show here that gankyrin has an antiapoptotic activity in cells exposed to DNA damaging agents. Downregulation o...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2005.06.006

    authors： Higashitsuji H,Higashitsuji H,Itoh K,Sakurai T,Nagao T,Sumitomo Y,Masuda T,Dawson S,Shimada Y,Mayer RJ,Fujita J

    更新日期：2005-07-01 00:00:00

  • Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway.

    abstract：:Homeostasis under hypoxic conditions is maintained through a coordinated transcriptional response mediated by the hypoxia-inducible factor (HIF) pathway and requires coactivation by the CBP and p300 transcriptional coactivators. Through a target-based high-throughput screen, we identified chetomin as a disrupter of HI...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2004.06.009

    authors： Kung AL,Zabludoff SD,France DS,Freedman SJ,Tanner EA,Vieira A,Cornell-Kennon S,Lee J,Wang B,Wang J,Memmert K,Naegeli HU,Petersen F,Eck MJ,Bair KW,Wood AW,Livingston DM

    更新日期：2004-07-01 00:00:00

  • Paradoxical Puma Prohibits Pyruvate Pumps to Prime Pathology.

    abstract：:PUMA is a pro-apoptotic Bcl-2 family protein that can act as a tumor suppressor or oncogene in different cancers. In this issue, Kim et al. show that PUMA, independent of its apoptotic function, enforces glycolytic metabolism by inhibiting the transport of pyruvate into the mitochondria, promoting hepatocellular carci...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccell.2019.01.016

    authors： Green DR

    更新日期：2019-02-11 00:00:00

  • Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype.

    abstract：:The childhood brain tumor, medulloblastoma, includes four subtypes with very different prognoses. Here, we show that paracrine signals driven by mutant β-catenin in WNT-medulloblastoma, an essentially curable form of the disease, induce an aberrant fenestrated vasculature that permits the accumulation of high levels o...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2016.03.002

    authors： Phoenix TN,Patmore DM,Boop S,Boulos N,Jacus MO,Patel YT,Roussel MF,Finkelstein D,Goumnerova L,Perreault S,Wadhwa E,Cho YJ,Stewart CF,Gilbertson RJ

    更新日期：2016-04-11 00:00:00

  • Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein.

    abstract：:Inactivation of the von Hippel-Lindau tumor suppressor gene is linked to the development of hereditary (VHL Disease-associated) and sporadic clear cell carcinoma of the kidney. The VHL gene product, pVHL, targets the heterodimeric transcription factor HIF for polyubiquitination, and restoration of pVHL function in VHL...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/s1535-6108(02)00043-0

    authors： Kondo K,Klco J,Nakamura E,Lechpammer M,Kaelin WG Jr

    更新日期：2002-04-01 00:00:00

  • Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma.

    abstract：:Our understanding of Ewing's sarcoma development mediated by the EWS/FLI fusion protein has been limited by a lack of knowledge regarding the tumor cell of origin. To circumvent this, we analyzed the function of EWS/FLI in Ewing's sarcoma itself. By combining retroviral-mediated RNA interference with reexpression stud...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2006.04.004

    authors： Smith R,Owen LA,Trem DJ,Wong JS,Whangbo JS,Golub TR,Lessnick SL

    更新日期：2006-05-01 00:00:00

  • m6A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program.

    abstract：:The dynamic and reversible N6-methyladenosine (m6A) RNA modification installed and erased by N6-methyltransferases and demethylases regulates gene expression and cell fate. We show that the m6A demethylase ALKBH5 is highly expressed in glioblastoma stem-like cells (GSCs). Silencing ALKBH5 suppresses the proliferation ...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2017.02.013

    authors： Zhang S,Zhao BS,Zhou A,Lin K,Zheng S,Lu Z,Chen Y,Sulman EP,Xie K,Bögler O,Majumder S,He C,Huang S

    更新日期：2017-04-10 00:00:00

  • BMP meets AML: induction of BMP signaling by a novel fusion gene promotes pediatric acute leukemia.

    abstract：:In this issue of Cancer Cell, Gruber et al. report that a significant proportion of children with acute megakaryoblastic leukemia acquire a translocation that confers enhanced BMP signaling and promotes self-renewal of hematopoietic progenitors. This study presents novel therapeutic targets that may lead to improved t...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccr.2012.10.008

    authors： Crispino JD,Le Beau MM

    更新日期：2012-11-13 00:00:00

  • Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases.

    abstract：:Deregulation of growth factor receptor tyrosine kinases (RTKs) is linked to a large number of malignancies. This occurs through a variety of mechanisms that result in enhanced activity of the receptor. Considerable evidence now supports the idea that loss of negative regulation plays an important role in receptor dere...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/s1535-6108(03)00136-3

    authors： Peschard P,Park M

    更新日期：2003-06-01 00:00:00

  • Cell signaling and cancer.

    abstract：:During the course of tumor progression, cancer cells acquire a number of characteristic alterations. These include the capacities to proliferate independently of exogenous growth-promoting or growth-inhibitory signals, to invade surrounding tissues and metastasize to distant sites, to elicit an angiogenic response, an...

    journal_title：Cancer cell

    pub_type： 杂志文章,评审

    doi：10.1016/s1535-6108(03)00216-2

    authors： Martin GS

    更新日期：2003-09-01 00:00:00

  • An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia.

    abstract：:To define the mutation spectrum in non-Down syndrome acute megakaryoblastic leukemia (non-DS-AMKL), we performed transcriptome sequencing on diagnostic blasts from 14 pediatric patients and validated our findings in a recurrency/validation cohort consisting of 34 pediatric and 28 adult AMKL samples. Our analysis ident...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2012.10.007

    authors： Gruber TA,Larson Gedman A,Zhang J,Koss CS,Marada S,Ta HQ,Chen SC,Su X,Ogden SK,Dang J,Wu G,Gupta V,Andersson AK,Pounds S,Shi L,Easton J,Barbato MI,Mulder HL,Manne J,Wang J,Rusch M,Ranade S,Ganti R,Parker M,

    更新日期：2012-11-13 00:00:00

  • Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth.

    abstract：:Antiangiogenic tumor therapy has failed in the adjuvant setting. Here we show that inhibition of the Tie2 ligand angiopoietin-2 (Ang2) effectively blocks metastatic growth in preclinical mouse models of postsurgical adjuvant therapy. Ang2 antibody treatment combines well with low-dose metronomic chemotherapy (LDMC) in...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2014.11.005

    authors： Srivastava K,Hu J,Korn C,Savant S,Teichert M,Kapel SS,Jugold M,Besemfelder E,Thomas M,Pasparakis M,Augustin HG

    更新日期：2014-12-08 00:00:00